Dibromobimane can be used to stabilize a primary loop in myosin subfragment 1 by crosslinking specific domains.
Answers are grounded in this paper and cite their sources.
May enable myosin loop stabilization in vitro; leaves open relevance to cardiac contractility in vivo.
A bifunctional fluorescent alkylating agent, dibromobimane, has been used to stabilize a preexisting primary loop in myosin subfragment 1 (S-1). The crosslink achieved joins Cys-707 (called sulfhydryl group "SH1") of the 20-kDa domain (formerly called "20K" domain) with a thiol of the 50-kDa domain and seems to place the dibromobimane near the ATP-perturbable tryptophan.
No takes yet. Share an insight, caveat, or question.
Mornet et al. (1985) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: